Skip to content
The Nexus
DossierENTITY

DESTINY-Breast03 trial

Coverage of DESTINY-Breast03 trial in the Nexus archive.

Earliest in view: Jul 13 · 16:02 UTCMost recent: Jul 13 · 16:02 UTC
Co-mentioned in this coverage
MedPage Todayorganization1trastuzumab deruxtecan (T-DXd; Enhertu)topic1HER2-positive metastatic breast cancertopic1
Recent coverage
  • HEALTHJul 13 · 16:02 UTCMEDPAGE TODAY
    Later-Line Treatments for HER2-Positive Breast Cancer

    Based on the DESTINY-Breast03 trial, trastuzumab deruxtecan (Enhertu) is now the preferred second-line therapy for HER2-positive metastatic breast cancer, according to guidelines.

DESTINY-Breast03 trial · Dossier · The Nexus